5/9/12

Anyone following this? Looks like a hostile takeover strategy case study. It covers staggered boards, proxy advisory firms, and poison pills. Really interesting. Is it gonna happen? If you were the adviser to Roche or Illumina, what would tell them?

Out of curiosity, how are hedgies and arbs playing this?

http://tradingevents.blogspot.com/

Comments (4)

5/9/12

Well Roche rescinded their bid, so it's over. Illumina won.
http://dealbook.nytimes.com/2012/04/18/illumina-fe...

MM IB -> TMT Corporate Development

Investment Banking Interview Course

5/10/12
SECfinance:

Well Roche rescinded their bid, so it's over. Illumina won.
http://dealbook.nytimes.com/2012/04/18/illumina-fe...

Look at their previous 2 major acquisitions. Both Ventana and Genentech took more than 6 months to buy. Do you really think it's over?

5/10/12
DarkPool:
SECfinance:

Well Roche rescinded their bid, so it's over. Illumina won.
http://dealbook.nytimes.com/2012/04/18/illumina-fe...

Look at their previous 2 major acquisitions. Both Ventana and Genentech took more than 6 months to buy. Do you really think it's over?

Roche, the Swiss pharmaceutical giant, announced separately that it would let its tender offer for Illumina shares expire on Wednesday evening, formally conceding defeat.

I think it's over for now. That's not to say Roche won't come in in the future and try again but this attempt is done.

MM IB -> TMT Corporate Development

5/9/12
Add a Comment